NovoCure stock jumps in premarket after FDA clears Optune Pax for pancreatic cancer
NovoCure stock surged about 23% to $12.91 before the bell Thursday, following word that the FDA signed off on its Optune Pax device for locally advanced pancreatic cancer.
